Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19078503 | 1.00 | MEN1 (0.47) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL17032291 | 0.90 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL7026410 | 0.90 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL6218492 | 0.90 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL15720999 | 0.90 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL23692789 | 0.90 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL18039756 | 0.88 | GAA (0.54) | ALDH1A1KMT2ATSHRRECQLGAA | |
| SCHEMBL17756103 | 0.84 | ALDH1A1 (0.48) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL12723118 | 0.83 | ALDH1A1 (0.47) | MEN1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL6907597 | 0.83 | ALDH1A1 (0.47) | MEN1ALDH1A1KMT2ATSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | Ecstasy LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2022-12-29 | — | — | US | disclosed |
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | Ecstasy LLC | 2020-06-09 | — | — | US | disclosed |
| CN-110662541-A | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2020-01-07 | — | — | CN | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018169818-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | WANG XIAODONG (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2018-09-13 | — | — | US | disclosed |
| US-9856262-B2 | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| WO-2013025425-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2420234-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| CN-101155797-A | 1H-benzimidazole-4-carboxamide compounds substituted at the 2-position with a quaternary carbon atom are potent PARP inhibitors | ABBOTT LAB (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | OPRM1, OPRL1, OPRK1 | MEN1 4685/4885ALDH1A1 825/4885KMT2A 1414/4885 |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | OPRM1, SIGMAR1, OPRK1 | MEN1 4637/4885ALDH1A1 1039/4885KMT2A 1818/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | MEN1 3097/4885ALDH1A1 332/4885KMT2A 595/4885 |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | MEN1 4685/4885ALDH1A1 825/4885KMT2A 1414/4885 |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | MEN1 4685/4885ALDH1A1 825/4885KMT2A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.